← Evidence map

ArticleJournal of cancer research and clinical oncology2025

Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies?

M Talarico et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

4 papers cite it

2025
2026
this papercites it

2 trials

Full record →Abstract, authors, funding and every citing paper · PMID 41065854